TMEM38B

Across TCGA pan-cancer cohorts, TMEM38B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM38B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM38B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM38B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where TMEM38B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.904	0.105	.008	23	view →
LSCC	DFS	Tertile	III,IV	1.000	0.625	.024	3	view →
GBM	OS	Tertile	All	0.747	0.968	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM38B–CCRCC (DFS)

Open the CCRCC breakdown →